Filing Details

Accession Number:
0001209191-24-000929
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-04 21:35:45
Reporting Period:
2024-01-03
Accepted Time:
2024-01-04 21:35:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1607678 Viking Therapeutics Inc. VKTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1264949 Greg Zante C/O Viking Therapeutics, Inc.
9920 Pacific Heights Blvd, Suite 350
San Diego CA 92121
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.00001 Per Share Acquisiton 2024-01-03 28,334 $0.00 188,724 No 4 A Direct
Common Stock, Par Value $0.00001 Per Share Disposition 2024-01-03 18,233 $17.40 170,491 No 4 F Direct
Common Stock, Par Value $0.00001 Per Share Acquisiton 2024-01-03 70,000 $0.00 240,491 No 4 A Direct
Common Stock, Par Value $0.00001 Per Share Disposition 2024-01-03 30,889 $17.40 209,602 No 4 F Direct
Common Stock, Par Value $0.00001 Per Share Disposition 2024-01-04 13,872 $18.58 195,730 No 4 F Direct
Common Stock, Par Value $0.00001 Per Share Disposition 2024-01-04 15,000 $17.90 180,730 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 F Direct
No 4 A Direct
No 4 F Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2024-01-03 155,000 $0.00 155,000 $17.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
155,000 2025-01-03 2034-01-03 No 4 A Direct
Footnotes
  1. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 33.34% of which vested on January 3, 2024 upon the achievement of a non-financial performance goal.
  2. Includes 1,169 shares acquired on May 19, 2023 and 9,942 shares acquired on November 20, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
  3. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares uponthe vesting of certain shares of common stock subject to certain performance restricted stock units.
  4. Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2014 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
  5. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted stock units.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.72 to $18.14, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares sold at each separate price.
  7. 25% of the shares subject to the option will vest on each anniversary of the grant date.